Health
Results: 4837-4848 of 9327

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

South Texas Blood and Tissue Center First US Civilian Blood Center to Install Velico's FrontlineODP™ System






